Analytical Data
-
Gene name
TOR1A
- Application
-
Alternative Names
TOR1A;DQ2;Torsin-1A
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14656
-
Expression Region
21-332aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MVEPISLGLA LAGVLTGYIY PRLYCLFAEC CGQKRSLSRE ALQKDLDDNL FGQHLAKKII LNAVFGFINN PKPKKPLTLS LHGWTGTGKN FVSKIIAENI YEGGLNSDYV HLFVATLHFP HASNITLYKD QLQLWIRGNV SACARSIFIF DEMDKMHAGL IDAIKPFLDY YDLVDGVSYQ KAMFIFLSNA GAERITDVAL DFWRSGKQRE DIKLKDIEHA LSVSVFNNKN SGFWHSSLIH RNLIDYFVPF LPLEYKHLKM CIRVEMQSRG YEIDEDIVSR VAEEMTFFPK EERVFSDKGC KTVFTKLDYY YDD
-
Molecular Weight
38 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TOR1A, also known as Torsin A, is a protein encoded by the TOR1A gene, which is primarily expressed in the brain and is crucial for normal neural function. Research into TOR1A has gained significant attention due to its association with DYT1 dystonia, a movement disorder characterized by involuntary muscle contractions and abnormal postures. Mutations in the TOR1A gene, particularly the deletion of a glutamic acid residue, are known to cause this hereditary disease, suggesting that the dysfunction of Torsin A plays a critical role in the pathophysiology of dystonia. Studies have indicated that TOR1A is involved in various cellular processes, such as protein homeostasis, cellular stress response, and the regulation of cytoskeletal dynamics. This protein is localized in the endoplasmic reticulum and is believed to participate in nuclear pore complex function and mitochondrial dynamics, which might be disrupted in dystonia patients. Understanding the molecular mechanisms underpinning TOR1A’s function and its role in DYT1 dystonia could pave the way for novel therapeutic strategies. Additionally, exploring the interactions of TOR1A with other cellular components may provide insights into its broader implications in neural development and potential links to other neurological disorders. As such, the ongoing investigation of TOR1A not only contributes to the understanding of dystonia but also highlights the complexities of protein function in the nervous system, with potential ramifications for treatments targeting similar disorders.











